PROJECTS & INITIATIVES
The Value of Treatment
“Value of Treatment: Bridging the Early Diagnosis and Treatment Gap for Brain Disorders”
EBC’s Value of Treatment project kicked off in January 2016 with a meeting and the release of the first EBC Discussion Paper “Exploring the potential for a holistic care model for brain disorders to close the treatment gap in Europe: development of a workable care model and case studies analysis” , and a comprehensive research framework for the case studies analysis.
The Value of Treatment research project draws from the EBC Report “The Economic Cost of Brain Disorders in Europe” published in 2005 (Balak and Elmaci 2007) and updated in 2010 (Gustavsson et al. 2011) that provided a solid estimation on the economic costs of brain disorders in Europe. The indirect costs of brain disorders make up for 40 percent of the total costs – which EBC estimated at around 800 billion euros per year in Europe.
In June 2017, the quantitative research of Value of Treatment: Round 1, with case studies analysis, was completed and released.
In 2018, the Value of Treatment: Round 2 began, with the formation of working groups in subsections of Mental Disorders and Rare Neurological Disorders. The 2nd phase, to run until 2021, will focus on bridging gaps and providing seamless, coordinated care.
The Value of Treatment Research Project ultimately provide evidence-based and cost-effective policy recommendations for the adoption and implementation of a more patient-centred and sustainable coordinated care model for brain disorders.
Learn more through the specific project pages:
The Value of Treatment (VoT) project is supported through financial contributions from:
*Biogen, BMS-Pfizer Alliance, Boehringer Ingelheim GmbH, Grünenthal, Janssen, Livanova, Lundbeck, Medtronic, MSD, Novartis, Pfizer, Roche, Takeda, TEVA Pharmaceuticals, UCB Biopharma, Vifor Pharma, EARLS and EURLSSG.
**Biomarin, European Psychiatric Association (EPA), Ipsen, Janssen, Reata Pharmaceuticals, Takeda